Advertisement
Advertisement

REGN

REGN logo

Regeneron Pharmaceuticals Inc

642.59
USD
Sponsored
-7.17
-1.10%
May 21, 16:00 UTC -4
Closed
exchange

After-Market

645.99

+3.40
+0.53%

Regeneron Pharmaceuticals Inc Profile

About

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.

Info & Links

CEO

Leonard S. Schleifer

Headquarters

777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.regeneron.com

Auditor

PricewaterhouseCoopers LLP

Share holders

164

Employees

15,410

Regeneron Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization2

67.73B

Enterprise Value

67.47B

Enterprise Value/EBITDA(ttm)

16.18

Price to Earnings Ratio(ttm)

21.28

Price to Sales(ttm)

5.66

Price to Book(mrq)

2.60

Price to Cash(ytd)

18.29

Profitability

Gross Margin(ttm)

85.33%

Operating Margin(ttm)

27.63%

Profit Margin(ttm)

31.30%

Return on Equity(ttm)

13.04%

Return on Invested Capital(ttm)

13.61%

Return on Assets(ttm)

10.13%

Income Statement

Revenue(ttm)

14.92B

Revenue Per Share(ttm)

142.31

Gross Profit(ttm)

12.61B

EBITDA(ttm)3

4.17B

Net Income Available to Common(ttm)

4.42B

Diluted EPS(ttm)

41.56

Share Statistics

Beta (5Y Monthly)

0.40

52-Week Change

4.52%

S&P 500 52-Week Change

27.39%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

104.84M

Dividend Yield

0.49%

Float4

98.30M

% Held by Insiders

7.02%

% Held by Institutions

83.31%

Balance Sheet

Total Cash(mrq)

8.75B

Total Cash Per Share(mrq)

83.50

Total Debt(mrq)

2.71B

Total Debt/Equity(mrq)

8.66%

Current Ratio(mrq)

4.13%

Quick Ratio(mrq)

3.39%

Book Value Per Share(mrq)

295.71

Cash Flow

Operating Cash Flow Per Share(ytd)

45.85

Free Cash Flow(ytd)

4.08B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement